Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi(TM) (lactic acid, citric acid and potassium bitartrate) in Contraception

Stock Information for Evofem Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evofem Biosciences Inc.

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AYX, EVFM, CNSL

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.